作为抗疟疾药的盖菲提尼布:揭示其治疗潜力
Varun Gorki1,2, Neha Sylvia Walter1,3, Monika Chauhan4
1Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, 160014, India.
Inflammopharmacology
|February 28, 2025
概括
格菲提尼布是一种蛋白氨酸激酶抑制剂,对菌株具有显著的抗疟疾活性. 结合gefitinib和artsunate提供了一个有希望的疟疾治疗策略,具有完全的寄生虫清除.
科学领域:
- 疟疾学和药物发现
- 寄生虫学的寄生虫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在Plasmodium spp.中的耐药性. 需要新的疟疾治疗方法.
- 药物再利用为识别新的抗疟疾药物提供了一种有效的策略.
- 蛋白氨酸激酶 (PTKs) 对等离子杆菌的发展和生存至关重要.
研究的目的:
- 为了研究PTK抑制剂gefitinib的抗疟疾潜力.
- 为了评估gefitinib的有效性,无论是在体和通过实验模型.
- 为了探索gefitinib与现有的抗疟疾药物结合的协同效应.
主要方法:
- 在分析以确定药物目标.
- 在体外对抗Plasmodium falciparum菌株的药物敏感性测试.
- 在感染Plasmodium berghei小鼠的体内疗效研究.
- 异构图分析以评估药物协同作用.
- 生物化学和组织病理学分析.
主要成果:
- 格菲提尼布对P. falciparum菌株 (IC50值为0.49和0.83微克/毫升) 显示出显著的抑制活性.
- 异构图分析表明gefitinib和artsunate之间存在实质性的协同作用.
- 格菲提尼布向了关键的寄生体酶,包括甲基转移酶,pfpk5和cdpk1.
- 在体内研究显示了剂量依赖的治疗活性和显著的化学抑制 (91.09%).
- 吉菲提尼布和阿尔特苏纳酸的组合实现了完全的寄生虫清除,没有复发.
结论:
- 盖菲提尼布通过向必不可少的Plasmodium激酶,表现出相当大的抗等离子体活性.
- 吉菲提尼布和阿尔特苏纳酸的联合治疗显示出在疟疾治疗中显著的前景.
- 对gefitinib的药理动力学特性进行进一步研究是有必要的.
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Antiepileptic Drugs: Potassium Channel Activators
140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
140
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
126
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
126
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K


